全球狼疮治疗市场 – 行业趋势及 2029 年预测

市场分析和规模

近年来，预计预测期内狼疮治疗市场将快速增长。美国狼疮基金会估计，150 万美国人患有狼疮，美洲每年有 16,000 例新病例。狼疮是一种慢性自身免疫性疾病，人体的免疫系统无法识别自身的细胞和组织并攻击它们。皮肤狼疮会攻击您的皮肤。皮肤狼疮影响约 10% 的所有狼疮病例，而皮肤狼疮影响 65% 的系统性红斑狼疮患者。

Data Bridge Market Research 分析称，2021 年狼疮治疗市场价值为 25.6205 亿美元，预计到 2029 年将达到 51.4263 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 9.10%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

狼疮是一种自身免疫性炎症疾病，人体免疫系统变得过度活跃并开始攻击健康组织。肿胀、炎症、皮疹和关节不适都是狼疮的常见症状。狼疮疗法是一种常用于治疗狼疮疾病的治疗方法。

报告范围和市场细分

Lupus Therapeutic Market Dynamics

Drivers

• Increasing prevalence of lupus

The rising prevalence of lupus is anticipated to influence the lupus therapeutic market's growth. Lupus is an autoimmune disease in which the immune system of the body becomes overactive and targets normal, healthy tissue. Inflammation, swelling, and damage to the joints, skin, kidneys, blood, heart, and lungs are some of the symptoms.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of lupus therapeutic market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the lupus therapeutic market. Additionally, high disposable income and increase in the demand for effective therapies will result in the expansion of lupus therapeutic market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the lupus therapeutic market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the lupus therapeutic market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of lupus will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the lupus therapeutic market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This lupus therapeutic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lupus therapeutic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Lupus is far more common in women. Women between the ages of 15 and 44 make up over 90% of those diagnosed with lupus. It is, however, available to persons of all genders and ages. Lupus commonly appears in children at the age of 12.

Lupus therapeutic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Lupus Therapeutic Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of lupus therapeutic in recent months.

Recent Development

• In August 2021, AstraZeneca had announced the approval of Food and Drug Administration (FDA) for Saphnelo (anifrolumab) in the US. Saphnelo is a first-in-class type I interferon receptor antibody that is the first novel treatment for patients with systemic lupus erythematosus in more than a decade.

Global Lupus Therapeutic Market Scope

The lupus therapeutic market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Systemic Lupus Erythematosus (SLE)
• Cutaneous Lupus Erythematosus,
• Drug-Induced Lupus Erythematosus
• Neonatal Lupus

Treatment

• Corticosteroids
• Immunosuppressive Drugs
• Biologic Drugs
• Antihypertensive Drugs
• Others

Diagnosis

• Laboratory Tests

• Antinuclear antibody (ANA) test
• Urinalysis
• Kidney and liver assessment
• Erythrocyte sedimentation rate
• Complete blood count

• Biopsy
• Imaging Tests

• Echocardiogram
• Chest X-ray

• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Lupus Therapeutic Market Regional Analysis/Insights

The Lupus therapeutic market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Lupus therapeutic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the lupus therapeutic market because of the growing prevalence of lupus in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和狼疮治疗市场份额分析

狼疮治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对狼疮治疗市场的关注有关。

红斑狼疮治疗市场的一些主要参与者包括：

• LEO Pharma A/S（丹麦）
• Zydus Cadila（印度）
• Amneal Pharmaceuticals LLC.（美国）
• Glenmark 制药有限公司（印度）
• Hikma Pharmaceuticals PLC（英国）
• Dr. Reddy's Laboratories Ltd.（印度）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• Bausch Health Companies Inc.（加拿大）
• 礼来公司 (美国)
• AbbVie Inc.（美国）
• 雅培（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 诺华公司（瑞士）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• 艾尔建（爱尔兰）
• 默克公司（美国）
• 住友公司（日本）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)

SKU-53306